Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Jun 25

PMID 26107769

Citations 10

Authors

Caroline J Aalbers

Lisette Bevaart

Scott Loiler

Karin de Cortie

J Fraser Wright

Federico Mingozzi

Paul P Tak

Margriet J Vervoordeldonk

Affiliations

Soon will be listed here.

Abstract

Introduction: Proof of concept for local gene therapy for the treatment of arthritis with immunomodulatory cytokine interferon beta (IFN-β) has shown promising results in animal models of rheumatoid arthritis (RA). For the treatment of RA patients, we engineered a recombinant adeno-associated serotype 5 vector (rAAV5) encoding human (h)IFN-β under control of a nuclear factor κB promoter (ART-I02).

Methods: The potency of ART-I02 in vitro as well as biodistribution in vivo in arthritic animals was evaluated to characterize the vector prior to clinical application. ART-I02 expression and bioactivity after transduction was evaluated in fibroblast-like synoviocytes (FLS) from different species. Biodistribution of the vector after local injection was assessed in a rat adjuvant arthritis model through qPCR analysis of vector DNA. In vivo imaging was used to investigate transgene expression and kinetics in a mouse collagen induced arthritis model.

Results: Transduction of RA FLS in vitro with ART-I02 resulted in high expression levels of bioactive hIFN-β. Transduction of FLS from rhesus monkeys, rodents and rabbits with ART-I02 showed high transgene expression, and hIFN-β proved bioactive in FLS from rhesus monkeys. Transgene expression and bioactivity in RA FLS were unaltered in the presence of methotrexate. In vivo, vector biodistribution analysis in rats after intra-articular injection of ART-I02 demonstrated that the majority of vector DNA remained in the joint (>93%). In vivo imaging in mice confirmed local expression of rAAV5 in the knee joint region and demonstrated rapid detectable and sustained expression up until 7 weeks.

Conclusions: These data show that hIFN-β produced by RA FLS transduced with ART-I02 is bioactive and that intra-articular delivery of rAAV5 drives expression of a therapeutic transgene in the joint, with only limited biodistribution of vector DNA to other tissues, supporting progress towards a phase 1 clinical trial for the local treatment of arthritis in patients with RA.

Citing Articles

Current Immunotherapy Strategies for Rheumatoid Arthritis: The Immunoengineering and Delivery Systems.

Zhang C, Ma P, Qin A, Wang L, Dai K, Liu Y Research (Wash D C). 2025; 6:0220.

PMID: 39902178 PMC: 11789687. DOI: 10.34133/research.0220.

Immunoengineering the next generation of arthritis therapies.

Klimak M, Nims R, Pferdehirt L, Collins K, Harasymowicz N, Oswald S Acta Biomater. 2021; 133:74-86.

PMID: 33823324 PMC: 8941669. DOI: 10.1016/j.actbio.2021.03.062.

Candidates for Intra-Articular Administration Therapeutics and Therapies of Osteoarthritis.

Toyoda E, Maehara M, Watanabe M, Sato M Int J Mol Sci. 2021; 22(7).

PMID: 33808364 PMC: 8036705. DOI: 10.3390/ijms22073594.

Liposomal Nanosystems in Rheumatoid Arthritis.

Ferreira-Silva M, Faria-Silva C, Viana Baptista P, Fernandes E, Ramos Fernandes A, Corvo M Pharmaceutics. 2021; 13(4).

PMID: 33801603 PMC: 8065723. DOI: 10.3390/pharmaceutics13040454.

Quantitative Whole-Body Imaging of I-124-Labeled Adeno-Associated Viral Vector Biodistribution in Nonhuman Primates.

Ballon D, Rosenberg J, Fung E, Nikolopoulou A, Kothari P, De B Hum Gene Ther. 2020; 31(23-24):1237-1259.

PMID: 33233962 PMC: 7769048. DOI: 10.1089/hum.2020.116.

References

Adriaansen J, Tas S, Klarenbeek P, Bakker A, Apparailly F, Firestein G . Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy. Ann Rheum Dis. 2005; 64(12):1677-84. PMC: 1755308. DOI: 10.1136/ard.2004.035063. View

Bevaart L, Vervoordeldonk M, Tak P . Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis?. Arthritis Rheum. 2010; 62(8):2192-205. DOI: 10.1002/art.27503. View

Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus M . Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010; 21(6):704-12. DOI: 10.1089/hum.2009.182. View

Lefevre S, Knedla A, Tennie C, Kampmann A, Wunrau C, Dinser R . Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med. 2009; 15(12):1414-20. PMC: 3678354. DOI: 10.1038/nm.2050. View

van de Sande M, Gerlag D, Lodde B, van Baarsen L, Alivernini S, Codullo V . Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Ann Rheum Dis. 2010; 70(3):423-7. DOI: 10.1136/ard.2010.139550. View

Nathwani A, Rosales C, McIntosh J, Rastegarlari G, Nathwani D, Raj D . Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther. 2011; 19(5):876-85. PMC: 3098629. DOI: 10.1038/mt.2010.274. View

Tak P, Kalden J . Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther. 2011; 13 Suppl 1:S5. PMC: 3123966. DOI: 10.1186/1478-6354-13-S1-S5. View

Favaro P, Finn J, Siner J, Wright J, High K, Arruda V . Safety of liver gene transfer following peripheral intravascular delivery of adeno-associated virus (AAV)-5 and AAV-6 in a large animal model. Hum Gene Ther. 2010; 22(7):843-52. PMC: 3135234. DOI: 10.1089/hum.2010.155. View

Mingozzi F, Chen Y, Edmonson S, Zhou S, Thurlings R, Tak P . Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene Ther. 2012; 20(4):417-24. PMC: 3473155. DOI: 10.1038/gt.2012.55. View

10.

Watson R, Broome T, Levings P, Rice B, Kay J, Smith A . scAAV-mediated gene transfer of interleukin-1-receptor antagonist to synovium and articular cartilage in large mammalian joints. Gene Ther. 2012; 20(6):670-7. PMC: 3577988. DOI: 10.1038/gt.2012.81. View

11.

Evans C, Robbins P, Ghivizzani S, Wasko M, Tomaino M, Kang R . Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci U S A. 2005; 102(24):8698-703. PMC: 1150836. DOI: 10.1073/pnas.0502854102. View

12.

Tak P, Gerlag D, Aupperle K, van de Geest D, Overbeek M, Bennett B . Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum. 2001; 44(8):1897-907. DOI: 10.1002/1529-0131(200108)44:8<1897::AID-ART328>3.0.CO;2-4. View

13.

Gao G, Alvira M, Wang L, Calcedo R, Johnston J, Wilson J . Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. 2002; 99(18):11854-9. PMC: 129358. DOI: 10.1073/pnas.182412299. View

14.

Lechman E, Keravala A, Nash J, Kim S, Mi Z, Robbins P . The contralateral effect conferred by intra-articular adenovirus-mediated gene transfer of viral IL-10 is specific to the immunizing antigen. Gene Ther. 2003; 10(24):2029-35. DOI: 10.1038/sj.gt.3302109. View

15.

Yan Z, Zak R, Zhang Y, Ding W, Godwin S, Munson K . Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia. J Virol. 2004; 78(6):2863-74. PMC: 353734. DOI: 10.1128/jvi.78.6.2863-2874.2004. View

16.

Holten J, Reedquist K, Sattonet-Roche P, Smeets T, Plater-Zyberk C, Vervoordeldonk M . Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther. 2004; 6(3):R239-49. PMC: 416442. DOI: 10.1186/ar1165. View

17.

Kremer J . Toward a better understanding of methotrexate. Arthritis Rheum. 2004; 50(5):1370-82. DOI: 10.1002/art.20278. View

18.

Tak P . IFN-beta in rheumatoid arthritis. Front Biosci. 2004; 9:3242-7. DOI: 10.2741/1475. View

19.

Alexander I, Russell D, Miller A . DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J Virol. 1994; 68(12):8282-7. PMC: 237296. DOI: 10.1128/JVI.68.12.8282-8287.1994. View

20.

Bologna C, Edno L, Anaya J, Canovas F, Vanden Berghe M, Jorgensen C . Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum. 1994; 37(12):1770-3. DOI: 10.1002/art.1780371210. View